TBI is one of the most common causes of death and disability in the world, usually resulting from blasts, falls, knocks, traffic accidents, and assaults. The proposed diagnostic tool is a fully-integrated, automated biosensor device which requires only a drop of blood to detect up to three biomarkers released by the brain after sustaining injury. The biomarker readings will be displayed on an easy-to-read screen, along with an indicator alerting the care giver to the severity of the injury. “This collaboration exemplifies the extension of “More-than-Moore” technologies to healthcare. Building on our core capabilities in silicon-based microfluidics and biosensor technology, we can help our partner create innovative diagnostic tools to improve TBI treatment,” says Prof. Dim-Lee Kwong, Executive Director of IME. “The TBI project is the start of a longer term collaboration that SFC will explore together with IME," commented by Dr. Sai Kumar, Vice President of Research and development, SFC Fluidics.